

Special Feature:**Breast tumour in a male with complete androgen insensitivity**C. Srinivasa Rao,¹ V Suresh,¹ S Sangeetha,¹ N Rukmangada²*Departments of ¹Endocrinology, ²Pathology, Sri Venkateswara Institute of Medical Sciences, Tirupati***Srinivasa Rao C, Suresh V, Sangeetha S, Rukmangada N. Breast tumour in a male with complete androgen insensitivity. J Clin Sci Res 2016;5:144-5. DOI: <http://dx.doi.org/10.15380/2277-5706.JCSR.16.03.004>.**

A 17-year-old phenotypically female patient presented with chief complaints of not attaining menarche and also of a swelling in the left breast. Physical examination revealed normal breast development, normal female external genitalia, sparse pubic hair, absent axillary hair and bilateral inguinal masses. Ultrasonography of abdomen showed absence of uterus and ovaries in the pelvis. Her hormonal evaluation revealed elevated testosterone of 6.9 ng/dL with raised leutinizing hormone (LH) 33.0 IU/L and normal follicular stimulating hormone (FSH) 5.6 IU/levels. Subsequent cytogenetic analysis confirmed 46 XY karyotype. She underwent excision of the breast swelling at a local hospital. Histopathological examination of the excised breast tissue was suggestive of multiple papilloma with hyperplasia of unusual type and immunohistochemistry markers positive for CK-5, p 63 and actin (Figures 1, 2 and 3).

Androgen insensitivity syndrome, previously called as testicular feminization syndrome, is a rare X-linked recessive condition. Morris et al, described this entity in 1963, and it has also been known as 'Morris syndrome'.¹ It is a form of male pseudohermaphroditism, i.e., male karyotype (XY) with a female phenotype. The defect is in androgen receptor that is normally present in the androgen responsive tissue which results in failure of normal masculinization of external genitalia in chromosomally male

Received: March 11, 2016; Accepted: March 14, 2016.

individuals.² This failure of masculinization can be either complete or partial depending on the amount of residual receptor function.³ In




Figure 1: Photomicrograph showing ducts lined by stratified cuboidal epithelial cells, arranged in the form of ill-defined papillary projections with surrounding sclerosis (Haematoxylin and eosin, × 200)




Figure 2: Photomicrograph showing mammary ducts with hyperplastic papillae lined by stratified cuboidal epithelial cells (Haematoxylin and eosin, × 400)

Corresponding author: Dr V. Suresh, Professor, Department of Endocrinology, Sri Venkateswara Institute of Medical Sciences, Tirupati, Indian.
e-mail: sureshvdrsmailbox@rediffmail.com

**Online access**

http://svimstpt.ap.nic.in/jcsr/apr-jun16_files/sf16.pdf
DOI: <http://dx.doi.org/10.15380/2277-5706.JCSR.16.03.004>




Figure 3: Photomicrograph showing the mammary ducts with cribriform pattern, lined by hyperplastic cuboidal epithelial cells (Haematoxylin and eosin, $\times 400$)

complete androgen insensitivity syndrome (CAIS), the individual has adequate breast development, normal female external genitalia, a vagina of variable depth, absent uterus, and sparse or absent pubic hair and axillary hair.⁴ The gonad (undescended testes) may be intra-abdominal, inguinal, or labial. They most often present in late adolescence with primary amenorrhoea. Breast tumours have not been previously reported in CAIS.

Breast tumours are rare in males but the risk is increased in those with androgen insensitivity caused by longer glutamine repeats in the androgen receptor seen with partial or minimal androgen insensitivity syndrome. Breast cancer

has not been reported in CAIS.⁵ The above case report illustrates a rare presentation of breast papilloma with hyperplasia of unusual type in a male with complete androgen insensitivity syndrome. All papillary lesions with atypical hyperplasia require surgical excision owing to the cancer risk in future.⁶

REFERENCES

1. Morris JM, Mahesh VB. Further observations on the syndrome, "Testicular Feminization Syndrome". *Am J Obst Gynecol* 1963; 15:731-45.
2. Coulam C, Grahm M, Spelsburg T. Androgen insensitivity: gonadal androgen receptor activity. *Am J Obstet Gynecol* 1984;150:531-3.
3. Viner RM, Test Y, Williams DM, Patterson MN. Androgen Insensitivity Syndrome: a survey of diagnostic procedures. *Arch Dis Child* 1997; 77: 305-9.
4. Rutgers JL, Scully RE. The androgen insensitivity syndrome (testicular feminization): a clinicopathologic study of 43 cases. *Int J GynecolPathol*1991;10:126-44
5. MacLean HE, Brown RW, Beilin J, et al. Increased frequency of long androgen receptor CAG repeats in male breast cancers. *Breast Cancer Res Treat.* 2004;88:239-46.
6. Gutman H, Schachter J, Wasserberg N, Shechtman I, Griff F. Are solitary breast papillomas entirely benign? *Arch surg* 2003;138:1330-3.